RT @synovialjoints: Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific
Tweet Content
Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific inflammatory pathways (IL-23, IL-12, Type I IFN). Listen to my interview with Prof. Oliver Fitzgerald on this and his highlights https://t.co/3UJCwbHsLC
@RheumNow #ACR21 Abst#490 https://t.co/OWZDHhcQ9q
Links
Emerging Therapies in Psoriatic Arthritis: Drs. Antoni Chan and Oliver FitzGera…
https://bit.ly/3bRd867
Show on Archive Page
On
Display in Search Results
On
PDQ
Off